US approval for Lyumjev

The FDA has approved Lilly’s Lyumjev rapid-acting mealtime insulin to reduce high blood sugar after meals and keep blood glucose levels in-range. This approval offers another important mealtime insulin option for adults with Type 1 or Type 2 diabetes and was approved in Japan and Europe in March 2020.

Lyumjev can be taken at the beginning of a meal (strongly recommended) or 20 minutes after starting it. This flexibility is due to the faster onset and offset of the insulin.

 

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).
Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags